Breakthrough in Treatment for World’s Leading Cause of Kidney Failure in Children

The commonest cause of kidney failure in children is due to toxin producing bacteria that enters the circulation through the gut resulting in a disease called Haemolytic Uraemic Syndrome (HUS). There are different types of HUS — the most common is called Shiga toxin-associated haemolytic uraemic syndrome (STEC-HUS). As one of the most common causes of kidney problems in people of all ages, it can be particularly devastating in young children, often requiring kidney dialysis, with around one in 20 children developing life-long kidney failure or dying.

STEC-HUS commonly happens after a gut infection, associated with bloody diarrhea. Exactly why the kidney is so susceptible to injury in STEC-HUS has until now, remained unclear. The research wanted to identify the mechanism underpinning the disease pathway.

Using laboratory models, the team found a specific cell in the kidney called the podocyte is targeted by the Shiga toxin and then ‘talks’ to local blood vessels causing small blood clots to form. This is due to the activation of the ‘complement’ pathway, and can lead to an eventual loss of kidney function.

Critically, the team demonstrated in both mouse models and in human kidney cells that STEC-HUS can be successfully treated by inhibiting the complement pathway early in the disease process with a drug called Eculizumab.

Richard Coward Consultant Paediatric Nephrologist said: “We have now discovered that a cell in the kidney called the podocyte is a key target cell of Shiga toxin and that it can be treated if the ‘complement’ pathway is blocked in the blood early in the disease.”

Dr Aisling McMahon added: “This research has not only shown exactly how Shiga toxin is able to target the kidney and cause such devastating damage but has also discovered a way in which HUS could be stopped in its tracks using a drug that is already in clinical use. This is another great example of the importance of research in identifying new treatment options for patients, and we look forward to the next steps in this project.”

The research team has demonstrated that early use of Eculizumab can prevent Shiga-toxin driven kidney failure and the drug has therapeutic potential for this devastating disease that can result in life-long dialysis, and death, for some children.

The next steps for the researchers will be to understand how quickly Eculizumab needs to be given and carry out more early trials in children with STEC-HUS.

Sources:

Emily E. Bowen, Jennifer A. Hurcombe, Fern Barrington, Lindsay S. Keir, Louise K. Farmer, Matthew D. Wherlock, Carolina G. Ortiz-Sandoval, Valentina Bruno, Arlette Bohorquez-Hernandez, Daniel Diatlov, Niyousha Rostam-Shirazi, Sara Wells, Michelle Stewart, Lydia Teboul, Abigail C. Lay, Matthew J. Butler, Robert J.P. Pope, Eva M.S. Larkai, B. Paul Morgan, John Moppett, Simon C. Satchell, Gavin I. Welsh, Patrick D. Walker, Christoph Licht, Moin A. Saleem, Richard J.M. Coward. Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation. Med, 2023; DOI: 10.1016/j.medj.2023.09.002

University of Bristol. “Breakthrough in treatment for world’s leading cause of kidney failure in children.” ScienceDaily. ScienceDaily, 19 October 2023. <www.sciencedaily.com/releases/2023/10/231019111223.htm>.

Materials provided by University of Bristol. Note: Content may be edited for style and length.

Images from:

Photo by Kelly Sikkema

https://unsplash.com/photos/woman-in-black-long-sleeve-shirt-holding-white-smartphone-xN0INdwHAs4